DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.11B
AUM Growth
+$3.11B
(+0.72%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-4.82%
Top 10 Holdings %
Top 10 Hldgs %
52.57%
Holding
75
New
6
Increased
18
Reduced
21
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$150M |
| 2 |
Axsome Therapeutics
AXSM
|
$83.7M |
| 3 |
Vaxcyte
PCVX
|
$45.5M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$34.6M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$25.1M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$264M |
| 2 |
BridgeBio Pharma
BBIO
|
$82M |
| 3 |
Guardant Health
GH
|
$62.1M |
| 4 |
RAPT Therapeutics
RAPT
|
$42.1M |
| 5 |
Amgen
AMGN
|
$35.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Guardant Health
GH
$8.41B
| $221M | 7.09% | 4,250,000 -1,193,721 | -22% | -$62.1M |
|
2
Ionis Pharmaceuticals
IONS
$6.79B
| $193M | 6.2% | 4,891,544 +327,337 | +7% | +$12.9M |
|
3
Protagonist Therapeutics
PTGX
$3.67B
| $179M | 5.75% | 3,245,899 +245,899 | +8% | +$13.6M |
|
4
Dynavax Technologies
DVAX
$1.19B
| $176M | 5.66% | 17,791,486 | – | – |
|
|
5
Insmed
INSM
$28.8B
| $176M | 5.65% | 1,750,000 +1,495,249 | +587% | +$150M |
|
6
Akero Therapeutics
AKRO
$3.74B
| $162M | 5.21% | 3,042,598 -167,672 | -5% | -$8.95M |
|
7
Immunovant
IMVT
$2.56B
| $152M | 4.87% | 9,500,000 | – | – |
|
8
Ocular Therapeutix
OCUL
$2.12B
| $133M | 4.25% | 14,294,420 | – | – |
|
|
9
Apellis Pharmaceuticals
APLS
$3.48B
| $121M | 3.89% | 7,000,000 +2,000,000 | +40% | +$34.6M |
|
10
Cytokinetics
CYTK
$4.23B
| $121M | 3.87% | 3,650,000 +576,147 | +19% | +$19M |
|
11
Structure Therapeutics
GPCR
$1.11B
| $106M | 3.41% | 5,133,917 +1,033,917 | +25% | +$21.4M |
|
12
89bio
ETNB
$1.34B
| $93.3M | 2.99% | 9,500,000 +183,667 | +2% | +$1.8M |
|
|
13
Axsome Therapeutics
AXSM
$6.05B
| $83.7M | 2.68% | +801,371 | New | +$83.7M |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $75.2M | 2.41% | 5,380,449 | – | – |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $70.9M | 2.27% | 1,750,000 +265,734 | +18% | +$10.8M |
|
|
16
Vaxcyte
PCVX
$4B
| $69.9M | 2.24% | 2,150,000 +1,400,000 | +187% | +$45.5M |
|
17
Nurix Therapeutics
NRIX
$714M
| $69.1M | 2.22% | 6,064,910 +564,910 | +10% | +$6.43M |
|
18
Geron
GERN
$893M
| $60.6M | 1.94% | 43,000,000 +4,823,749 | +13% | +$6.8M |
|
19
Immunocore
IMCR
$1.62B
| $56.5M | 1.81% | 1,800,000 +388,598 | +28% | +$12.2M |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $49.1M | 1.57% | 1,350,000 | – | – |
|
|
MAZE
21
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $48.5M | 1.55% | 3,948,910 +679,784 | +21% | +$8.34M |
|
22
ANI Pharmaceuticals
ANIP
$2.03B
| $45.7M | 1.46% | 700,000 | – | – |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $42.3M | 1.36% | 1,350,000 +350,000 | +35% | +$11M |
|
24
Dianthus Therapeutics
DNTH
$759M
| $41.6M | 1.33% | 2,233,148 -124,554 | -5% | -$2.32M |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $40.7M | 1.31% | 2,000,000 | – | – |
|